Logo image of ALXN

Alexion Pharm Inc (ALXN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALXN -

182.5
+3.05 (+1.7%)
Last: 7/20/2021, 9:56:13 PM
183
+0.5 (+0.27%)
After Hours: 7/20/2021, 9:56:13 PM
Fundamental Rating

3

ALXN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While ALXN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALXN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALXN had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 9.15%
PM (TTM) 10.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

There is no outstanding debt for ALXN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 5.06 indicates that ALXN is not in any danger for bankruptcy at the moment.
ALXN has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 4.52 indicates that ALXN has no problem at all paying its short term obligations.
A Quick Ratio of 3.96 indicates that ALXN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 3.96

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.94% over the past year.
Measured over the past years, ALXN shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.12% on average per year.
ALXN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.24%.
ALXN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.44% yearly.
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%

3.2 Future

The Earnings Per Share is expected to grow by 6.32% on average over the next years.
The Revenue is expected to grow by 7.94% on average over the next years.
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALXN Yearly Revenue VS EstimatesALXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ALXN Yearly EPS VS EstimatesALXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 14.22, which indicates a correct valuation of ALXN.
ALXN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 12.48, ALXN is valued correctly.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.35, ALXN is valued a bit cheaper.
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
ALXN Price Earnings VS Forward Price EarningsALXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.39
ALXN Per share dataALXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

ALXN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.44
PEG (5Y)0.71
EPS Next 2Y8.02%
EPS Next 3Y8.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Alexion Pharm Inc

NASDAQ:ALXN (7/20/2021, 9:56:13 PM)

After market: 183 +0.5 (+0.27%)

182.5

+3.05 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-22 2022-02-22/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners0.8%
Ins Owner Change0%
Market Cap40.34B
Revenue(TTM)6.26B
Net Income(TTM)681.80M
Analysts66.2
Price Target180.9 (-0.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA 13.39
EPS(TTM)12.83
EY7.03%
EPS(NY)14.62
Fwd EY8.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS28.33
BVpS56.24
TBVpSN/A
PEG (NY)1.44
PEG (5Y)0.71
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.15%
PM (TTM) 10.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 3.96
Altman-Z 5.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Alexion Pharm Inc / ALXN FAQ

Can you provide the ChartMill fundamental rating for Alexion Pharm Inc?

ChartMill assigns a fundamental rating of 5 / 10 to ALXN.


Can you provide the valuation status for Alexion Pharm Inc?

ChartMill assigns a valuation rating of 3 / 10 to Alexion Pharm Inc (ALXN). This can be considered as Overvalued.


What is the profitability of ALXN stock?

Alexion Pharm Inc (ALXN) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for ALXN stock?

The Price/Earnings (PE) ratio for Alexion Pharm Inc (ALXN) is 14.22 and the Price/Book (PB) ratio is 3.24.


What is the expected EPS growth for Alexion Pharm Inc (ALXN) stock?

The Earnings per Share (EPS) of Alexion Pharm Inc (ALXN) is expected to grow by 9.86% in the next year.